Skip to main content

Advertisement

Table 3 Median (range) of serological parameters and cell subsets of patients treated with MMF or CYC compared to controls

From: Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus

Madian (range) serological parameters and cell subsets MMF CYC Controls
(number = 25) (number = 20) (number = 22)
anti-dsDNA (U/ml) 38 (0 to 927) 38 (0 to 7536) 28 (0 to 963)
C3c (g/L) 0.8 (0.4 to 1.1) 0.8 (0.5 to 1.5) 0.8 (0.2 to 1.4)
FLCkappa (mg/L) 19.0 (9.6 to 52.0)aab 34.9 (1.6 to 246.0)aa 26.7 (9.2 to 148.0)b
FLClambda (mg/L) 21.8 (10.0 to 47.8)b 30.2 (4.1 to 153.0) 32.8 (12.9 to 99.3)b
IgG (g/L 10.5 (4.9 to 16.3)b 11.8 (3.8 to 28.8) 13.4 (5.9 to 24.2)b
IgA (g/L) 2.1 (0.2 to 5.7)aab 3.3 (1.1 to 6.7)aa 2.8 (0.9 to 7.4)b
IgM (g/L) 0.9 (0.3 to 5.5) 1.1 (0.3 to 2.6) 1.1 (0.3 to 7.4)
lymphocytes (/μl) 800 (220 to 2160) 790 (230 to 1910) 890 (190 to 2310)
leukocytes (/μl) 6010 (2640 to 11450) 5835 (2400 to 14008) 6195 (2160 to 10700)
platelets (× 103/μl) 259 (170 to 451)bb 238 (68 to 355) 211 (47 to 325)bb
CD19 + B lymphocytes (/μl) 55.6 (2.8 to 365.0) 31.2 (4.8 to 206.1)c 103.0 (14.7 to 277.4)c
- CD27++CD38++ (/μl) 0.8 (0.0 to 7.4)aaaabb 7.3 (0.1 to 90.9)aaaa 2.5 (0.7 to 61.4)bb
- HLADRhighCD27++CD38++ (/μl) 0.4 (0.0 to 4.3)aaaabbb 4.3 (0.1 to 58.6)aaaa 1.8 (0.5 to 55.1)bbb
- HLADRlowCD27++CD38++ (/μl) 0.3 (0.0 to 3.2)aaaa 2.1 (0.0 to 32.3)aaaa 1.0 (0.2 to 6.3)
- CD27+IgD (/μl) 4.0 (1.1 to 168.1) 6.2 (0.9 to 47.2) 10.2 (3.8 to 52.6)
- CD27+IgD+ (/μl) 0.9 (0.1 to 9.0) 0.8 (0.2 to 4.1)cc 2.2 (0.4 to 7.7)cc
- CD27IgD+CD38+ (/μl) 26.2 (0.2 to 232.9)a 3.2 (0.0 to 106.4)acccc 50.7 (2.5 to 118.3)cccc
- CD27IgD (/μl) 10.0 (0.9 to 28.8) 7.0 (1.0 to 38.5) 14.2 (1.7 to 108.5)
- CD27IgD+CD38++ (/μl) 2.3 (0.0 to 59.1) 2.4 (0.1 to 82.5) 4.9 (0.2 to 48.6)
CD3 + T lymphocytes (/μl) 463.4 (79.9 to 1562.0) 469.1 (120.5 to 1263.0) 616.0 (92.7 to 1675.0)
CD4+ (/μl) 317.2 (72.7 to 1142.0) 254.9 (88.6 to 858.2) 445.7 (46.6 to 1307.0)
- CD44+CD62L (/μl) 23.4 (2.2 to 178.6) 26.5 (5.4 to 126.8) 28.5 (5.2 to 334.5)
- CD45RACD45RO+ (/μl) 105.5 (15.4 to 514.9) 120.2 (24.8 to 506.7) 148.2 (22.9 to 754.8)
- CD45RA+CD45RO (/μl) 144.5 (27.7 to 511.3) 119.6 (19.9 to 534.7) 114.9 (19.0 to 633.9)
CD8+ (/μl) 112.6 (2.0 to 538.0) 140.8 (17.2 to 334.6) 142.6 (20.9 to 618.0)
- CD44+CD62L (/μl) 21.5 (0.3 to 363.8) 33.4 (4.9 to 227.8) 15.3 (2.8 to 541.4)
- CD45RACD45RO+ (/μl) 16.1 (0.3 to 332.2) 31.5 (5.3 to 142.9) 24.6 (4.7 to 357.8)
- CD45RA+CD45RO (/μl) 77.1 (1.4 to 485.8) 80.6 (10.5 to 250.1) 86.1 (4.9 to 370.5)
CD4CD8 (/μl) 28.0 (2.2 to 97.2) 23.1 (6.2 to 98.4) 22.1 (2.9 to 174.2)
- CD44+CD62L (/μl) 5.7 (0.1 to 71.6) 6.8 (1.5 to 38.3) 6.3 (1.0 to 166.0)
- CD45RACD45RO+ (/μl) 9.2 (0.1 to 43.0) 8.5 (0.5 to 55.8) 10.9 (0.7 to 68.6)
- CD45RA+CD45RO (/μl) 17.9 (0.7 to 70.2) 12.7 (5.0 to 44.6) 13.3 (1.7 to 160.2)
CD123 + CD11c HLA-DR high PDCs (/μl) 1.8 (0.4 to 8.5) 2.0 (0.4 to 6.2) 0.8 (0.1 to 20.6)
  1. Statistically significant differences (Dunn’s multiple comparisons test) were observed between patients receiving MMF and CYC (a) or controls (b) and patients receiving CYC versus controls (c) one (P <0.05), two (P <0.01), three (P <0.001), four (P <0.0001) symbols abc. C3c: complement factor C3c; CD4+ T cells; CD4CD8: double negative T cells; CD8+ T cells; CD27++CD38++: plasmablasts and plasma cells; CD27+IgD+: pre-switched memory B cells; CD27+IgD: post-switched memory B cells; CD27IgD+CD38+: naïve B cells; CD27IgD+CD38++: transitional B cells; CD27IgD: double negative B cells; CD44+CD62L: effector T cells; CD45RA+CD45RO: naïve T cells; CD45RACD45RO+: memory T cells; CD123+CD11cHLA-DRhighPDCs: plasmacytoid dendritic cells; controls: patients with SLE not receiving MMF or CYC; CYC: cyclophosphamide; FLC: free light chains; HLADRhighCD27++CD38++: plasmablasts; HLADRlowCD27++CD38++: plasma cells; Ig: immunoglobulin; MMF: mycophenolate mofetil; SLE, systemic lupus erythematosus.